Want to see ROIV full AI Analyst Report?

Roivant Sciences (ROIV) Price & Analysis

734 Followers

ROIV Stock Chart & Stats

$35.01

-$0.09(-0.26%)

At close: Jul 24 4:00 PM EDT

$35.01

-$0.09(-0.26%)

Day’s Range― - ―

52-Week Range$11.60 - $37.97

Previous CloseN/A

Volume4.04M

Average Volume (3M)5.59M

Market Cap

$26.22B

Enterprise Value$22.46K

Total Cash (Recent Filing)$3.84B

Total Debt (Recent Filing)$107.15M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Nov 16, 2026

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding722,323,000

10 Day Avg. Volume4,163,867

30 Day Avg. Volume5,587,777

Financial Highlights & Ratios

PEG Ratio-0.81

Price to Book (P/B)4.25

Price to Sales (P/S)2326.88

P/FCF Ratio-25.34

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$42.25

Price Target Upside20.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-1.35

Revenue Forecast (FY)$58.47M

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet And Funding CapacityVery low leverage and substantial equity provide financial flexibility to fund clinical programs, absorb setbacks and pursue commercialization without near-term dependence on debt markets.

Broad Pipeline And Development PlatformMultiple programs across immunology and inflammation diversify development risk and create several paths to future product revenue, while Roivant’s centralized capabilities can support execution across its Vant network.

Potential Expansion Of Commercial Product PortfolioA potential brepocitinib approval would add a commercial asset and give Roivant an opportunity to build recurring product revenue, patient-support infrastructure and launch capabilities across additional indications.

Bears Say

Substantial Ongoing Cash BurnHeavy cash consumption means the company remains dependent on its balance sheet, settlements or future partnering proceeds to sustain development, increasing funding pressure if clinical or commercial milestones are delayed.

Weak Revenue And Profitability ProfileLimited and declining revenue has not yet covered operating costs, leaving returns negative and earnings volatile. This reduces financial predictability until products achieve broader and more durable commercialization.

Clinical, Regulatory And Uptake UncertaintyThese risks can reduce the probability, timing or commercial value of pipeline outcomes. JAK safety concerns may also constrain physician and payer adoption even if brepocitinib receives regulatory approval.

Roivant Sciences News

Roivant Sciences price target raised to $37 from $35 at BofA

BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $37 from $35 and...

14d ago

ROIV

Roivant Sciences price target raised to $46 from $42 at Citi

Citi raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy...

14d ago

ROIV

Roivant Sciences price target raised to $42 from $36 at Guggenheim

Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $36 and keeps a Buy...

17d ago

ROIV

Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $34...

17d ago

ROIV

TD Cowen boosts Roivant Sciences price target, says has many catalysts on deck

TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $50 from $41 and keeps a...

17d ago

ROIV

Roivant Sciences reports Q1 EPS (26c), consensus (36c)

Reports Q1 revenue $1.44M, consensus $2.34M. “This quarter has been a moment of relative quiet between our incredibly...

18d ago

ROIV

Roivant Sciences price target raised to $35 from $31.50 at BofA

BofA raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $31.50 and keeps a Neutral...

23d ago

ROIV

Roivant Sciences Earnings Call: Cash-Rich, Catalyst-Heavy

Roivant Sciences Ltd. (($ROIV)) has held its Q1 earnings call. Read on for the main highlights of the...

5d ago

ROIV

Arbutus initiates patent infringement actions against Pfizer, BioNTech

Arbutus Biopharma (ABUS) and its exclusive licensee, Genevant Sciences, a subsidiary of Roivant (ROIV), announced the filing of...

1M ago

PFE

ABUS

Roivant Sciences price target raised to $40 from $35 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on Roivant Sciences (ROIV) to $40 from $35 and...

3M ago

ROIV

Roivant Sciences price target raised to $36 from $30 at Guggenheim

Guggenheim analyst Yastin Suneja raised the firm’s price target on Roivant Sciences (ROIV) to $36 from $30 and...

3M ago

ROIV

Roivant Sciences Earnings Call Highlights High-Impact Pipeline

Roivant Sciences Ltd. (($ROIV)) has held its Q4 earnings call. Read on for the main highlights of the...

3M ago

ROIV

SiTime, Photronics, Icici, Roivant, Marqeta Shake Markets

Insiders have been trading these 5 stocks: (($SITM)), (($PLAB)), (($IBN)), (($ROIV)) and (($MQ)). Here is a breakdown of...

4M ago

IBN

Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio

Roivant Sciences ( ($ROIV) ) has provided an update. On April 2, 2026, Roivant announced that its subsidiary...

5M ago

ROIV

ROIV FAQ

What was Roivant Sciences Ltd.’s price range in the past 12 months?

Roivant Sciences Ltd. lowest stock price was $11.60 and its highest was $37.97 in the past 12 months.

What is Roivant Sciences Ltd.’s market cap?

Roivant Sciences Ltd.’s market cap is $26.22B.

When is Roivant Sciences Ltd.’s upcoming earnings report date?

Roivant Sciences Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 84 days.

How were Roivant Sciences Ltd.’s earnings last quarter?

Roivant Sciences Ltd. released its earnings results on Aug 06, 2026. The company reported -$0.335 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.035.

Is Roivant Sciences Ltd. overvalued?

According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences Ltd. pay dividends?

Roivant Sciences Ltd. does not currently pay dividends.

What is Roivant Sciences Ltd.’s EPS estimate?

Roivant Sciences Ltd.’s EPS estimate is -0.36.

How many shares outstanding does Roivant Sciences Ltd. have?

Roivant Sciences Ltd. has 722,323,000 shares outstanding.

What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?

Roivant Sciences Ltd. reported an EPS of -$0.335 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went up 1.503%.

Which hedge fund is a major shareholder of Roivant Sciences Ltd.?

Currently, no hedge funds are holding shares in ROIV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Roivant Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

5.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Roivant Sciences (ROIV) Earnings & Revenues

Historic Earnings Reports

ROIV Company Deck

ROIV Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.View all ROIV earnings summaries

ROIV Stock 12 Month Forecast

Average Price Target

$42.25

▲(20.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.91,35.1476923076923,36.38538461538461,37.62307692307692,38.86076923076923,40.098461538461535,41.33615384615384,42.57384615384615,43.81153846153846,45.04923076923077,46.286923076923074,47.52461538461539,48.76230769230769,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.91,34.551538461538456,35.19307692307692,35.83461538461538,36.47615384615384,37.11769230769231,37.75923076923077,38.40076923076923,39.04230769230769,39.683846153846154,40.325384615384614,40.96692307692308,41.60846153846154,{"y":42.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.91,34.1476923076923,34.38538461538461,34.62307692307692,34.86076923076923,35.098461538461535,35.33615384615384,35.573846153846155,35.81153846153846,36.04923076923077,36.286923076923074,36.52461538461539,36.762307692307694,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.83,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.03,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >